Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial
To describe the 6-year safety and efficacy of etanercept (ETN) in children with extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related arthritis (ERA), and psoriatic arthritis (PsA)
Background: Apremilast is an oral phosphodiesterase 4 inhibitor approved for treatment of psoriasis and psoriatic arthritis (PsAs). The aim of this study was to evaluate the efficacy and safety of apremilast in a real-life cohort of patients with plaque psoriasis.
Background: The IL-17 receptor blocker brodalumab (BRO) was investigated in PsA in two double-blind, placebo (PBO)-controlled, phase III trials. Although terminated early by sponsor decision, sufficient patients were recruited to allow a meaningful evaluation of efficacy and safety.
Psoriasis is an inflammatory skin disease typically characterized by erythema, plaques and scaling. Proinflammatory cytokines including TNF- α, IL-23, and IL-17 are upregulated in psoriatic lesions and promote hyperproliferation of keratinocytes. Furthermore, psoriasis is seen as a systemic inflammatory disease associated with psoriatic arthritis, obesity and cardiometabolic comorbidities. Obesity negatively affects psoriasis disease se verity by producing proinflammatory adipokines by adipocytes and infiltrated immune cells and aggravates furthermore the cardiovascular risk in psoriasis patients.
Background: Psoriasis, psoriatic arthritis, atopic dermatitis (AD), hidradenitis suppurativa (HS) and chronic urticaria (CU) are associated with sleep disturbances (SD). Validated, disease-specific instruments are needed to assess SD in these populations. This work focuses on the development of the ‘PsO Sleepy-Q’ for psoriasis and ‘PsA Sleepy-Q’ for psoriatic arthritis.
Background: The International Dermatology Outcome Measures has established a core domain set for psoriasis clinical trials, including ‘PsA Symptoms.’ We sought to determine whether patients enrolling in a psoriasis trial should first be screened for PsA and then which measure should be used to assess ‘PsA Symptoms.’
Introduction: Psoriasis (PSO) and psoriatic arthritis (PsA) often affect women of childbearing age; but it is unclear if these women ( ♀) feel able to make informed treatment decisions around pregnancy and breastfeeding. This survey gained insight on disease management and pregnancy, to assess if they feel adequately supported. Methods: Women (18–45 years) with chronic inflammatory diseases from the US, Japan, and Germany, Fran ce, UK, Italy and Spain (EU5) participated in a 20-min online survey (Jul–Oct 2017; InSites Consulting).
Background: Psoriasis and psoriatic arthritis (PsA) are associated with a high prevalence of metabolic syndrome and increased risk of diabetes. Apremilast, an oral phosphodiesterase 4 inhibitor, was efficacious in the treatment of patients (pts) with moderate to severe psoriasis in the phase 3 ESTEEM 1 and 2 (EST) and phase 3b LIBERATE trials and in the treatment of pts with active PsA in the phase 3 PALACE 1 –3 trials (PAL). To explore the potential effect of apremilast on A1c concentrations, we assessed A1c in pts receiving placebo (PBO) or apremilast in a pooled analysis of EST, LIBERATE, and PAL.
Background/Purpose: The collaborative management of patients with psoriatic arthritis (PsA), involving dermatology and rheumatology teams, offers potential to close major gaps in PsA care, including underdiagnosis and undertreatment. In the context of an accredited educational program on collaborative PsA care, we conducted a survey study to assess perceptions and practices regarding the shared management of PsA patients among US dermatologists and rheumatologists.
This study aims to assess the real-world effectiveness of SEC in Canadian patient s with Pso, analyzing patient demographics, treatment patterns, and impact on disease/QoL at 1 year.
Introduction: Secukinumab is a totally human monoclonal antibody that selectively binds to the IL-17A and blocks its interaction with the IL-17 receptor, inhibiting the release of several proinflammatory cytokines. Secukinumab has been approved for the treatment of psoriasis in moderate-severe plaques on 2015. The experience published so far suggests that the response to the biological therapy in those patients who present psoriatic arthritis as comorbidity may be inferior in relation to those patients who do not have it.